Commentary Open Access
Extracts from Nicotiana glauca as a therapeutic strategy against rhabdomyosarcoma
Natalia Frattini1, Lucía Pronsato1, Andrea Vasconsuelo1, Lorena Milanesi1,*
- 1Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur (UNS), Bahía Blanca, Argentina, Universidad Nacional del Sur (UNS)- CONICET, Bahía Blanca, Argentina
Corresponding Author
Milanesi Lorena, milanesi@criba.edu.ar
Received Date: November 03, 2025
Accepted Date: December 23, 2025
Natalia F, Lucía P, Andrea V, Lorena M. Extracts from Nicotiana glauca as a therapeutic strategy against rhabdomyosarcoma. J Biomed Res. 2026;7(1):9-11.
Copyright: © 2026 Natalia F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Harnessing innovation for the future of breast cancer management
Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancerrelated mortality in women worldwide. Incidence rates continue to rise globally. Breast cancer encompasses a heterogeneous group of tumors with varying molecular features, clinical behaviors, and responses to therapy. While survival rates have improved, challenges persist such as invasive cancers, recurrent metastatic disease, and mortality among subgroups.
A scoping review of outcome measures in ovarian cancer clinical trials
The incorporation of patient-reported outcomes (PROs) is essential for assessing whether a cancer treatment enhances overall patient well-being, beyond merely extending survival. This scoping review aimed to identify and analyze the use of PROs in ovarian cancer clinical trials.
Significance of BRCA genetic testing for preoperative breast cancer patients
Examining BRCA mutations in preoperative breast cancer patients is very important when selecting a surgical procedure. Although there are advantages and disadvantages associated with knowing about the presence of genetic mutations, including for the patient’s family, there are many benefits for the patient. BRCA genetic testing should be recommended for patients who are strongly suspected of being positive for a BRCA mutation.
Molecular signatures of aggressive pediatric liver cancer
Liver masses account for 5 to 6% of pediatric cancer, which includes hepatoblastoma (HBL) along with rare cases of hepatocellular carcinoma (HCC). The most dangerous form of pediatric liver cancer is aggressive HBL, which can be characterized by chemo-resistance and multiple nodules or metastases at diagnosis, all correlating with worse clinical prognosis. Despite intensive studies and a significant improvement in overall outcomes, very little is known about the key molecular pathways which determine the aggressiveness of pediatric liver cancer.
Deregulation of Slug/Snail2 and TGF-β crosstalk in airway epithelial stem/progenitor cells: A key link between COPD and lung cancer?
This commentary focuses on two recent publications showing deregulation of the transcription factor Slug/Snail2 and TGF-β function in primary bronchial basal/progenitor cells of patients with Chronic Obstructive Pulmonary Disease (COPD) and the impact on proliferation and the expression of genes involved in stem cell maintenance. We discuss the molecular mechanisms related to the exhaustion of airway basal stem/progenitor cells in tobacco smoke-induced COPD, as well as putative links between COPD and lung cancer at the molecular level.